Craneware's (CRW) Buy Rating Reaffirmed at Shore Capital

Shore Capital reaffirmed their buy rating on shares of Craneware (LON:CRW - Free Report) in a report released on Wednesday morning, MarketBeat Ratings reports. Shore Capital currently has a GBX 2,650 ($35.57) target price on the stock.

Separately, Berenberg Bank assumed coverage on Craneware in a research note on Wednesday. They issued a "buy" rating and a GBX 2,800 ($37.58) price target for the company.

Craneware Price Performance

CRW stock traded down GBX 20 ($0.27) during midday trading on Wednesday, hitting GBX 2,460 ($33.02). The company's stock had a trading volume of 31,352 shares, compared to its average volume of 81,196. Craneware has a 12 month low of GBX 1,330 ($17.85) and a 12 month high of GBX 2,580 ($34.63). The company has a quick ratio of 1.00, a current ratio of 0.63 and a debt-to-equity ratio of 12.22. The firm has a market capitalization of £1.06 billion, a price-to-earnings ratio of 90.89 and a beta of 0.28. The company has a 50 day moving average of GBX 2,128.04 and a two-hundred day moving average of GBX 1,944.

Insider Transactions at Craneware

In other news, insider Will Whitehorn acquired 1,911 shares of Craneware stock in a transaction on Thursday, April 24th. The shares were acquired at an average price of GBX 1,584 ($21.26) per share, with a total value of £30,270.24 ($40,631.19). 19.28% of the stock is currently owned by insiders.

About Craneware

The Craneware Group, the market leader in automated value cycle solutions, including 340B management, collaborates with U.S. healthcare providers to plan, execute, and monitor operational and financial performance so they can continue to deliver quality care to their communities. Customers choose The Craneware Group's Trisus data and applications platform as their key to navigating the journey to financially sustainable value-based care.